Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 01-22 15:00:00

27.25

-0.15

-0.55%

High27.52	Low27.22	Vol17.50M
Open27.40	D1 Closing27.40	Amplitude1.09%
Mkt Cap72.76B	Tradable Cap57.72B	Total Shares2.67B
T/O478.00M	T/O Rate0.83%	Tradable Shares2.12B
P/B1.52	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":27.25,"timestamp":1769065201000,"preClose":27.4,"halted":0,"volume":17499633,"delay":0,"changeRate":-0.0055,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"Closed","change":-0.15,"latestTime":"01-22 15:00:00","open":27.4,"high":27.52,"low":27.22,"amount":478000000,"amplitude":0.0109,"askPrice":27.26,"askSize":54,"bidPrice":27.25,"bidSize":395,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769131800000},"marketStatusCode":5,"adr":0,"adjPreClose":27.4,"symbolType":"stock","openAndCloseTimeList":[[1769045400000,1769052600000],[1769058000000,1769065200000]],"highLimit":30.14,"lowLimit":24.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.52,"roa":"--","peRate":22.167087,"roe":"5.3%","epsLYR":1.04,"committee":0.774524,"marketValue":72769000000,"turnoverRate":0.0083,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":20.24,"timestamp":1769069298005,"preClose":20.44,"halted":0,"volume":2622442,"delay":0,"premium":"-33.57"},"floatMarketCap":57729000000},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"2605495015","title":"Shanghai Fosun Pharma - Approval by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495015?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:25","pubTimestamp":1769084719,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN05C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600196","BK0188","BK0060","BK0012","BK0187","BK0096","BK0175","BK0196","BK0028","BK0239","BK0183"],"gpt_icon":0},{"id":"2605495013","title":"Shanghai Fosun Pharma - Drug Registration Application for Norepinephrine Bitartrate Injection Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495013?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:25","pubTimestamp":1769084719,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN05C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK0188","BK0196","BK0175","BK0028","BK0187","BK0239","BK0183","600196","BK0060","BK0012"],"gpt_icon":0},{"id":"2605495004","title":"Shanghai Fosun Pharmaceutical Subsidiary Receives Drug Registration Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495004","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495004?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:25","pubTimestamp":1769084712,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co., Ltd. announced that a subsidiary has received approval for drug registration. According to the company, the approval covers a pharmaceutical product and is expected to further enrich the group's product line. The company noted that the sales performance following market launch may be subject to various factors, including demand, market competition, and sales channels, and investors are advised to consider associated risks. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL8pzrg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","BK1230","BK0187","00656","BK0183","BK0012","BK0196","BK0096","BK0175","BK0028","600196","BK0239"],"gpt_icon":0},{"id":"2605498326","title":"Fosun Pharma Subsidiary Fosun Adgenvax Plans Spin-Off Listing on Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2605498326","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605498326?lang=en_us&edition=fundamental","pubTime":"2026-01-22 19:20","pubTimestamp":1769080815,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Proposes Spin-Off Listing of Subsidiary Fosun Adgenvax. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL8DSvmj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0175","BK0196","BK0060","BK0096","BK0028","600196","00656","BK0012","BK0183","BK1230","BK0188","BK0239"],"gpt_icon":0},{"id":"2605049834","title":"Shanghai Fosun Pharma - Proposed Spin-off Listing of Fosun Adgenvax on Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2605049834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605049834?lang=en_us&edition=fundamental","pubTime":"2026-01-22 19:20","pubTimestamp":1769080804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YM1OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0096","BK0183","BK0239","BK0175","BK0188","BK0196","BK0187","600196","BK0060","BK0012"],"gpt_icon":0},{"id":"2605462998","title":"BRIEF-Shanghai Fosun Pharmaceutical To Spin Off Unit For Hong Kong Float","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462998","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605462998?lang=en_us&edition=fundamental","pubTime":"2026-01-22 18:10","pubTimestamp":1769076637,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharmaceutical To Spin Off Unit For Hong Kong FloatJan 22  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS IT PLANS TO SPIN OFF UNIT FOR HONG KONG FLOATSource textFurther company coverage: 600196.SS  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4N3YN0OU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0239","BK0183","BK0196","BK0096","BK0012","600196","BK0175","BK0060","BK0188","BK0028"],"gpt_icon":0},{"id":"2605462691","title":"Shanghai Fosun Pharma  Says It Plans to Spin off Unit for Hong Kong Float","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462691","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605462691?lang=en_us&edition=fundamental","pubTime":"2026-01-22 18:10","pubTimestamp":1769076637,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4N3YN0OU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0196","BK0060","BK0012","BK0239","BK0096","BK0175","BK0188","BK0183","600196","BK0187"],"gpt_icon":0},{"id":"2605830177","title":"Sisram Medical Signs MOU for Localisation Cooperation with Sinmait Medical in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2605830177","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605830177?lang=en_us&edition=fundamental","pubTime":"2026-01-21 17:14","pubTimestamp":1768986887,"startTime":"0","endTime":"0","summary":"Sisram Medical Ltd. has announced the signing of a memorandum of understanding  with Sinmait Medical Technology  Co., Ltd., an indirect wholly owned subsidiary of Shanghai Fosun Pharmaceutical  Co., Ltd. The MOU sets the framework for a possible cooperation aimed at promoting localisation in the People’s Republic of China. The cooperation is still subject to the signing of definitive agreements and may or may not proceed. If finalised, the partnership may constitute a notifiable and/or connected transaction under Hong Kong listing rules. Sisram Medical will provide further updates as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDLNRVL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0012","BK0239","00656","BK0188","BK0060","BK1585","BK0187","BK0175","BK0196","BK0183","01696","BK1230","600196","BK1100","BK0096","BK1593"],"gpt_icon":0},{"id":"2605124912","title":"Fosun Pharmaceutical Gets Nod for Colorectal Cancer Drug Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2605124912","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605124912?lang=en_us&edition=fundamental","pubTime":"2026-01-21 11:36","pubTimestamp":1768966583,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained approval from China's National Medical Products Administration for phase Ib/II clinical trials of HLX701, according to a Wednesday filing on the Shanghai bourse.The drug will be tested within the mainland in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0060","BK1593","BK1515","BK0096","BK0028","BK0196","BK0239","02196","BK0188","BK0175","BK1191","600196","BK0187","BK0012"],"gpt_icon":0},{"id":"2604150884","title":"InSilico Medicine Signs CNS Drug Deal With Hygtia Therapeutics; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604150884","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604150884?lang=en_us&edition=fundamental","pubTime":"2026-01-20 10:15","pubTimestamp":1768875331,"startTime":"0","endTime":"0","summary":"InSilico Medicine  entered into a global licensing and co-development agreement with Hygtia Therapeutics to advance its ISM8969 program, valuing the deal at up to HK$514.8 million, according to a Tuesday Hong Kong bourse filing.Hygtia Therapeutics is an incubate of Shenzhen Pengfu Biopharmaceutical Industry Private Equity Investment Fund Partnership Enterprise of Fosun Health Capital and Shanghai Fosun Pharmaceutical .Under the agreement, Insilico and Hygtia will co-develop ISM8969, an oral, brain-penetrant NLRP3 inhibitor for central nervous system  disorders, with each party holding 50% of the global rights.Insilico is eligible to receive up to $66 million in upfront and milestone payments, including a $10 million upfront payment due within 30 days, the filing said.InSilico shares rose nearly 4% in morning trade Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK1515","BK1191","BK4139","600196","BK4135","BK0196","BK0239","CNS","BK4007","BK0028","LENZ","BK0187","BK1593","BK4539","03696","BK0175","BK0060","BK0012","BK0188","02196","BK0096"],"gpt_icon":0},{"id":"2603091694","title":"BRIEF-Shanghai Fosun Pharma Says Drug Application Of Erythromycin Lactobionate For Injection Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2603091694","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603091694?lang=en_us&edition=fundamental","pubTime":"2026-01-14 18:22","pubTimestamp":1768386175,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says Drug Application Of Erythromycin Lactobionate For Injection Accepted By NMPAJan 14  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG APPLICATION OF ERYTHROMYCIN LACTOBIONATE FOR INJECTION ACCEPTED BY NMPAFurther company coverage: 600196.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0096","BK0012","BK0060","BK0175","600196","BK0188","BK0183","BK0196","BK0028","BK0239"],"gpt_icon":0},{"id":"2603691720","title":"Shanghai Fosun Pharma - Drug Application of Erythromycin Lactobionate for Injection Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2603691720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603691720?lang=en_us&edition=fundamental","pubTime":"2026-01-14 17:59","pubTimestamp":1768384799,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0196","BK0060","BK0012","BK0239","BK0096","BK0175","BK0188","BK0183","600196","BK0187"],"gpt_icon":0},{"id":"2601369313","title":"Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369313","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369313?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:11","pubTimestamp":1767874273,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said the resubmitted drug registration application for the Foritinib Succinate Capsules was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug was developed by Shanghai Fosun Pharmaceutical , a unit of the company.The indication for the acceptance is for the treatment of patients with anaplastic lymphoma kinase -positive locally advanced or metastatic non-small cell lung cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0028","600196","ALK.AU","BK0060","BK4585","BK4588","BK0188","BK7506","BK4500","BK0187","BK0239","ALK","BK7104","BK0012","BK1191","BK0096","BK1593","BK4008","02196","BK0175","BK0183","BK1515"],"gpt_icon":0},{"id":"2601035005","title":"BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2601035005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601035005?lang=en_us&edition=fundamental","pubTime":"2026-01-08 18:26","pubTimestamp":1767867975,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate CapsulesJan 8  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG REGISTRATION APPLICATION OF FORITINIB SUCCINATE CAPSULES ACCEPTED BY NMPAFurther company coverage: 600196.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y81OO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0060","BK0175","600196","BK0183","BK0239","BK0012","BK0188","BK0187","BK0096","BK0196"],"gpt_icon":0},{"id":"2601350796","title":"Shanghai Fosun Pharma - Drug Registration Application of Foritinib Succinate Capsules Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601350796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601350796?lang=en_us&edition=fundamental","pubTime":"2026-01-08 18:24","pubTimestamp":1767867862,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y81OO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0183","BK0028","BK0187","BK0096","BK0196","BK0175","BK0060","600196","BK0239","BK0012"],"gpt_icon":0},{"id":"1168579641","title":"Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1168579641","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168579641?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:36","pubTimestamp":1767864984,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., recently had a new drug registration...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK1191","02196","BK0239","BK1515","BK1593","BK0012","BK0196","BK0175","BK0096","BK0183","600196","BK0187","BK0188","BK0028"],"gpt_icon":0},{"id":"2601854238","title":"Fosun Pharmaceutical-Backed Fund Completes Private Fund Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854238","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854238?lang=en_us&edition=fundamental","pubTime":"2026-01-06 10:07","pubTimestamp":1767665247,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said an investment fund it participates in has completed its private equity fund filing with the Asset Management Association of China.The CR  Pharmaceutical Industry Equity Investment Fund was jointly established by Fosun Pharma's controlling subsidiary and 11 other investors in October 2025, according to a filing with the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0060","BK0175","BK0183","BK1593","BK0239","BK0012","BK0096","BK1191","BK0188","BK0187","02196","600196","BK0196","BK1515"],"gpt_icon":0},{"id":"2595597791","title":"Chengdu Xingrui Jingxuan Therapeutics Launches Phase I Trial for Prostate Cancer Radiopharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2595597791","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595597791?lang=en_us&edition=fundamental","pubTime":"2025-12-30 19:23","pubTimestamp":1767093787,"startTime":"0","endTime":"0","summary":"Fosun Pharma Subsidiary Chengdu Xingrui Jingxuan Initiates Phase I Clinical Trial of SRT-007 for Prostate Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDLbgWMzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0188","BK0196","BK1230","BK0175","00656","BK0028","BK0187","BK0239","BK0183","600196","BK0060","BK0012"],"gpt_icon":0},{"id":"1131238372","title":"Fosun Pharma's 1.4 Billion Yuan Bet on Discontinued Drug Draws Scrutiny Amid Efficacy Doubts","url":"https://stock-news.laohu8.com/highlight/detail?id=1131238372","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131238372?lang=en_us&edition=fundamental","pubTime":"2025-12-23 20:50","pubTimestamp":1766494226,"startTime":"0","endTime":"0","summary":"On December 22, Fosun Pharma (600196.SH; 02196.HK) responded to a regulatory inquiry from the Shanghai Stock Exchange regarding its 1.412 billion yuan investment in Green Valley (Shanghai)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0187","BK0175","BK0188","BK0239","BK0060","BK1515","BK1191","BK0096","BK0028","600196","02196","BK1593","BK0012","BK0196"],"gpt_icon":0},{"id":"1119459692","title":"Fosun Pharma's $1.4B Bet on Controversial Alzheimer's Drug: What's the Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1119459692","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119459692?lang=en_us&edition=fundamental","pubTime":"2025-12-21 16:10","pubTimestamp":1766304635,"startTime":"0","endTime":"0","summary":"Fosun Pharma (600196.SH; 02196.HK) has drawn regulatory scrutiny after its controlling subsidiary announced plans to acquire a 53% stake in Shanghai Green Valley Pharmaceuticals (Green Valley) for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK1593","02196","BK1191","BK0183","BK1515","BK0028","BK0096","BK0012","BK0175","BK0060","600196","BK0187","BK0196","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0239},{"period":"1month","weight":0.0066},{"period":"3month","weight":-0.0509},{"period":"6month","weight":0.0397},{"period":"1year","weight":0.17},{"period":"ytd","weight":0.0344}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0509},{"period":"3month","weight":0.0496},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.2696},{"period":"ytd","weight":0.0373}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","serverTime":1769091469877,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}